Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic eyes RNAi

This article was originally published in The Gray Sheet

Executive Summary

Collaboration with RNA-interference (RNAi) company Alnylam Pharmaceuticals will pursue development of novel drug-device combinations to treat neurodegenerative disorders. Huntington's disease will be the initial focus. The products will employ Medtronic infusion systems for targeted brain delivery of disease-specific, gene-silencing RNA segments. Under the agreement, Medtronic will be responsible for late-stage development and commercialization following equity investments in Cambridge, Mass.-based Alnylam...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts